Global Scabies Treatment Market - 2023-2030

Overview

The global scabies treatment market experiencing significant growth in recent years owing to the increasing prevalence of scabies. Scabies, an itchy skin rash mainly by sarcoptes scabiei var hominis. Globally, it is estimated to affect more than 200-400 million people every year.

The treatment of scabies includes topical agents like permethrin cream, sulphur ointment, and benzyl benzoate emulsion among others, and oral agents like ivermectin. Ivermectin, an oral agent should not be taken by pregnant women or children who weigh less than 15 kg. Other treatments may be needed to treat the complications of scabies. In such cases, antiseptics or antibiotics are used to treat such types of bacterial skin infections.

Owing to the increasing prevalence of scabies, increasing awareness and diagnosis, changing lifestyles, rising demand for innovative therapeutics, increasing demand for effective homecare treatments, increasing clinical trials and research activities, and technological advancements in treatment options are the major factors expected to drive the global scabies treatment market over the forecast period.

Dynamics

Increasing Demand for Innovative Therapeutics Drives the Growth of the Scabies Treatment Market

There is an increasing demand for innovative treatment options such as soaps, oral agents and other topical agents for enhanced treatment of scabies. Scabies is mainly treated with prescription anti-mite medications. In addition, home remedies can help scabies patients to get rid of scabies faster. The treatments such as tea tree oil, oatmeal baths, and over-the-counter (OTC) antihistamines, work effectively with prescription treatments to relieve itching and prevent spreading the scabies to others.

For instance, on June 28, 2023, Piramal Pharma Limited's Consumer Products Division, unveiled the Icy Cool variant of Tetmosol soap, which effectively treats skin conditions such as scabies, rashes, and itching, also offering a unique solution to reduce body temperature by 6 degrees, shielding against heat and combating skin infections.

There are many ongoing clinical trials and research activities for the development of the innovative treatment options which shows enhanced and better patient outcomes. Though there are Ivermectin and topical treatments, such as permethrin, are currently considered as first-line treatments, but, still there is an increasing demand for innovative therapeutics in coming years with better treatments.

Increasing Awareness and Early Detection Also Drive the Growth of the Scabies Treatment Market

Increasing awareness and early detection increases the growth of the scabies treatment market. Many awareness campaigns take the initiative to treat and increase awareness about scabies, which prompts individuals to seek medical attention, care, and treatment earlier when they experience symptoms like intense itching and skin rashes, it doesn't lead to complications. Early diagnosis allows for timely treatment, which can prevent the spread of scabies and reduce the risk of complications.

For instance, on August 24, 2022, Murdoch Children's Research Institute's Sarah Andersson and Professor Andrew Steer from the World Scabies Program are leading the mass drug administration(MDA) program with the Solomon Islands Ministry of Health and Medical Services, which will deliver ivermectin to the whole population. It's the first country-wide MDA in the world for the treatment of scabies.

Governments and healthcare organizations focus on awareness and treatment initiatives, even by conducting surveys on increasing prevalence, leading to improved disease control strategies and better access to treatment. Increasing awareness also promotes the adoption of preventive measures, such as maintaining good hygiene and avoiding close contact with infected individuals, which can help reduce the incidence of scabies.

For instance, on December 01, 2022, The Praja Arogya Vedika (PAV) appealed to the Andhra Pradesh government to get an intensive survey done on the prevalence of scabies in the Alluri Sitarama Raju district and check its spread by ensuring proper hygiene and providing medical aid.

Side Effects Associated with Therapeutics Will Hamper the Growth of the Market

There are many side effects associated with the scabies therapeutics which results in other types of skin infections. Some of the topical therapeutics, such as creams and lotions, cause skin irritation, redness, or itching at the application site, even leading to other types of skin infections. This can be uncomfortable for patients and may lead to discontinuation of treatment.

For instance, skin irritation, including itching, swelling, and redness, may occur with scabies and temporarily worsen after treatment with permethrin. Mild burning or stinging may also occur.

In some cases, individuals with scabies face allergic reactions due to drug-drug interactions or drug-food interactions with certain ingredients in scabies medications, leading to allergic reactions, such as hives or swelling. Severe allergic reactions are rare but can be concerning.

Segment Analysis

The global scabies treatment market is segmented based on type, treatment type, route of administration, distribution channel and region.

The Topical Agents from the Treatment Type Segment Accounted for Approximately 35.9% of the Scabies Treatment Market Share

Topical agents plays a crucial role in the treatment of scabies, their wide availability, enhanced treatment effectiveness, and cost-effectiveness dominate the market share. Topical agents are the most widely preferred therapeutics, such as creams, suspensions, lotions, and ointments, which are applied directly to the affected skin to eradicate the scabies mites and alleviate the associated itching and inflammation.

For instance, on August 2, 2021, ParaPRO, a specialty pharmaceutical company focused on innovative anti-parasitic treatments, announced the availability of Natroba (spinosad) Topical Suspension, 0.9%, the first product for scabies to be approved by the U.S. Food and Drug Administration (FDA) in more than 30 years. Earlier this year, the company received FDA approval for its supplemental New Drug Application (sNDA) for Natroba as a targeted topical treatment for scabies infestations in adult and pediatric patients four years of age and older.

The topical agents are relatively easy to apply and very convenient to use at home. The topical agents do not require invasive procedures or injections. Generally, topical agents are generally considered as safe for use in most individuals, including children and pregnant women. Compared to the other treatment options, topical agents are cost-effective, making them a preferred choice for patients with limited financial backgrounds.

Geographical Penetration

North America Accounted for Approximately 39.9% of the Market Share in 2022, Owing to the Increasing Prevalence and Advanced Healthcare Infrastructure

Scabies is a common condition worldwide, and due to the high population in North America, there is a high prevalence of scabies especially in the United States and Canada. Due to the region's high prevalence, there is continues rising demand for the various scabies treatment options.

For instance, according to an article published by Oxford Academy, Scabies is among the 50 most common infectious diseases worldwide. It is estimated that over 300 million cases of scabies occur annually, 1 million of which are in the United States.

North America is a well-known region for its advanced and well-established healthcare infrastructure, including well-equipped hospitals, dermatology clinics, and research facilities. Due to the high prevalence, this, in turn, allows for better diagnosis and treatment of scabies patients with appropriate and enhanced treatment, leading to a higher demand for scabies treatment products.

Competitive Landscape

The major global players in the scabies treatment market include: HH Pharma, Merck & CO., Inc., Trio Lifescience Private Limited., Incepta Pharmaceuticals Ltd., PalsonsDerma, Abbott Laboratories, NuLife Pharmaceuticals, Teva Pharmaceutical Industries Ltd, Amneal Pharmaceuticals LLC, and Aurobindo Pharma among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global scabies treatment market. During the pandemic, there is a fear of contracting COVID-19 or lockdown measures that have led some patients to avoid healthcare facilities, resulting in delayed or missed visits, scabies diagnoses, and treatments.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global scabies treatment market. Due to the conflict, the pharmaceutical companies and research institutions in the affected regions redirected their resources and attention away from scabies treatment research and development and performing clinical trials, which is directly impacting the global scabies treatment market.

By Type

• Typical Scabies
• Nodular Scabies
• Contagious or Norwegian scabies

By Treatment Type

• Topical Agents
• Permethrin cream
• Crotamiton lotion and Crotamiton cream
• Sulfur ointments
• Lindane lotion
• Benzyl benzoate (with or without tea tree oil)
• Others
• Oral Agents
• Ivermectin
• Others

By Route of Administration

• Topical
• Oral
• Intravenous

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• On July 01, 2022, The Ministry of Health announced the preparation of a mass drug distribution campaign targeting scabies and yaws at the community level. As part of the preparation, a three days Training of Trainers for the rollout of scabies and yaws drugs was conducted by the Ministry of Health. Totally, 45 participants including nurses, pharmacists, and health promotion staff from 8 provinces, including staff from the World Scabies Program and the Neglected Tropical Disease unit.
• In April 2022, WHO carried out community mapping in collaboration with Community Health Workers led by UNHCR. The survey provided an assessment of the extent of the ongoing scabies infestation amongst Rohingya displacement camps in Cox's Bazar. WHO and partners confirmed 18,505 scabies cases, crossing the 10% transmission threshold for required mass drug administration. Since then, the health sector has scaled up scabies case management at the camp level, coordinating with partners to ensure the rapid mobilization of routine medications. Support from the WASH sector and Risk Communication and Community Engagement (RCCE) has proved effective in helping communities spot and protect themselves from scabies cases.

Why Purchase the Report?

• To visualize the global scabies treatment market segmentation based on type, treatment type, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of scabies treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global scabies treatment market report would provide approximately 69 tables, 67 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies